BCM
AZN icon

Brooktree Capital Management’s AstraZeneca AZN Stock Holding History

Brooktree Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-200
Closed -$18K – 51
2020
Q1 		$18K Buy
+200
New +$18.8K 0.02% 81

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Brooktree Capital Management's AZN Position: Q2 2020 in Review

Brooktree Capital Management sold out of AstraZeneca (AZN) in Q2 2020, closing a stake of 200 shares — an estimated $18K sold.

Brooktree Capital Management first reported a position in AZN in Q1 2020 and held it in 1 quarter. The position peaked at $18K in Q1 2020. 668 funds tracked by Wall St. Rank hold AZN as of Q2 2020.

  • Brooktree Capital Management reported no remaining AstraZeneca position as of Q2 2020 after selling out during the quarter.
  • Brooktree Capital Management sold 200 AstraZeneca shares in Q2 2020, an estimated $18K.
  • Brooktree Capital Management first reported a position in AstraZeneca in Q1 2020 and held it in 1 quarter.
  • Brooktree Capital Management's AstraZeneca position peaked at $18K in Q1 2020.
  • 668 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2020.

Based on Brooktree Capital Management's 13F filing for Q2 2020, filed 3 Aug 2020.